^
    Back
    Association details:
    Biomarker:TLR4-L
    Cancer:Bladder Cancer
    Drug:gemcitabine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Cell Dev Biol
    Title:

    Toll-Like Receptor 4 as a Favorable Prognostic Marker in Bladder Cancer: A Multi-Omics Analysis

    Published date:
    06/01/2021
    Excerpt:
    Patients with low TLR4 levels are more sensitive to gemcitabine rather than cisplatin.
    DOI:
    10.3389/fcell.2021.651560